<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="189">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02271529</url>
  </required_header>
  <id_info>
    <org_study_id>13-14</org_study_id>
    <nct_id>NCT02271529</nct_id>
  </id_info>
  <brief_title>Zilver PTX Delivery System</brief_title>
  <official_title>Zilver Paclitaxel(PTX) Thumbwheel Delivery System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cook</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cook</source>
  <oversight_info>
    <authority>New Zealand: Health and Disability Ethics Committees</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the performance of the Zilver PTX stent
      thumbwheel delivery system.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Percent Change in Stent Length Upon Deployment</measure>
    <time_frame>Immediately following completion of the stent placement procedure</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>Drug Eluting Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zilver® Paclitaxel(PTX)® Drug-Eluting Peripheral Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zilver® PTX® Drug-Eluting Peripheral Stent</intervention_name>
    <description>Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.</description>
    <arm_group_label>Drug Eluting Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has symptomatic vascular disease of the native above-the-knee femoropopliteal
             arteries

          -  Patient has atherosclerotic lesion of the above-the-knee femoropopliteal artery

        Exclusion Criteria:

          -  Patient is &lt; 18 years of age

          -  Patient unable to complete required follow-up assessments

          -  Patient unwilling to sign and date the informed consent

          -  Simultaneous participation in another investigational drug or device study

          -  Pregnant, breastfeeding or planning to become pregnant in the next 5 years

          -  Additional medical/anatomical restrictions as specified in the Clinical Investigation
             Plan
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Holden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Auckland District Health Board</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Frankston Hospital</name>
      <address>
        <city>Frankston</city>
        <zip>Vic 3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <zip>Qld 4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg - Bad Krozingen GmbH</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>D-79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3248</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital</name>
      <address>
        <city>Wellington</city>
        <zip>3248</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 29, 2016</lastchanged_date>
  <firstreceived_date>October 17, 2014</firstreceived_date>
  <firstreceived_results_date>January 29, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Vascular Disease</keyword>
  <keyword>Femoral Artery</keyword>
  <keyword>Drug-Eluting Stent</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zilver® Paclitaxel(PTX)® Drug-Eluting Peripheral Stent</title>
          <description>Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zilver® Paclitaxel(PTX)® Drug-Eluting Peripheral Stent</title>
          <description>Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="67" spread="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change in Stent Length Upon Deployment</title>
        <time_frame>Immediately following completion of the stent placement procedure</time_frame>
        <safety_issue>No</safety_issue>
        <population>There were 63 implanted stents, an assessment of stent length change was not available for 2 stents.</population>
        <group_list>
          <group group_id="O1">
            <title>Zilver® Paclitaxel(PTX)® Drug-Eluting Peripheral Stent</title>
            <description>Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Stents analyzed</title>
            <units>Stents</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Percent Change in Stent Length Upon Deployment</title>
            <units>percentage of change in stent length</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.0" spread="2.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Under the assumption that the mean percent change in stent length upon deployment being 0.2% with a standard deviation of 4%, type I error of 0.05, and two one-sided t-tests, a sample size of at least 30 stents provides power &gt; 0.90 to determine that the mean length change of stents deployed with the thumbwheel delivery system is within +/-10%.</non_inferiority_desc>
            <p_value>&lt;0.01</p_value>
            <method>two one-sided t-tests</method>
            <param_type>Mean percent change</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Zilver® Paclitaxel(PTX)® Drug-Eluting Peripheral Stent</title>
          <description>Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Extensive metastatic disease of the abdomen and pelvis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Ooze from left groin access site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vascular injury requiring intervention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott Snyder, Director, Clinical Affairs</name_or_title>
      <organization>Cook Research Incorporated</organization>
      <phone>765-463-7537</phone>
      <email>SSnyder@medinst.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
